GRI Bio (GRI) Competitors

0.49

-0.02 (-4.49%)

(As of 06:33 PM ET)

GRI vs. NMTR, GNPX, SLRX, HSTO, PKBO, LSDI, ENTO, PXMD, ADXS, and EVFM

Should you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include 9 Meters Biopharma (NMTR), Genprex (GNPX), Salarius Pharmaceuticals (SLRX), Histogen (HSTO), Peak Bio (PKBO), Lucy Scientific Discovery (LSDI), Entero Therapeutics (ENTO), PaxMedica (PXMD), Ayala Pharmaceuticals (ADXS), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical products" industry.

GRI Bio vs.

GRI Bio (NASDAQ:GRI) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

: 34.0% of GRI Bio shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 3.0% of GRI Bio shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: GRI Bio has a beta of -1.7, meaning that its stock price is 270% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRI Bio
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
9 Meters Biopharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: 9 Meters Biopharma received 37 more outperform votes than GRI Bio when rated by MarketBeat users.
Company Underperform Outperform
GRI Bio N/A N/A
9 Meters Biopharma Outperform Votes
37
71.15%
Underperform Votes
15
28.85%
: In the previous week, GRI Bio had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for GRI Bio and 0 mentions for 9 Meters Biopharma. GRI Bio's average media sentiment score of 0.62 beat 9 Meters Biopharma's score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.
Company Overall Sentiment
GRI Bio Positive
9 Meters Biopharma Neutral
: GRI Bio's return on equity of -331.02% beat 9 Meters Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
GRI Bio N/A -331.02% -174.48%
9 Meters Biopharma N/A -584.97% -159.45%
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GRI Bio N/A N/A -$13.04M N/A N/A
9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Underperform	Outperform
GRI Bio	N/A	N/A
9 Meters Biopharma	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%

Company	Overall Sentiment
GRI Bio	Positive
9 Meters Biopharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-331.02%	-174.48%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$13.04M	N/A	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Summary

GRI Bio beats 9 Meters Biopharma on 6 of the 9 factors compared between the two stocks.

Ad Porter & Company

War on Elon Escalates…

One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?

Watch my new exposé and find out.

Get GRI Bio News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export to Excel

Metric	GRI Bio	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$264,000.00	$7.51B	$5.54B	$8.25B
Dividend Yield	N/A	4.29%	4.28%	4.09%
P/E Ratio	N/A	20.26	143.39	18.84
Price / Sales	N/A	267.00	1,661.47	72.46
Price / Cash	N/A	37.09	37.32	31.81
Price / Book	0.09	5.90	4.80	4.54
Net Income	-$13.04M	$150.77M	$111.90M	$224.06M
7 Day Performance	-6.71%	9.37%	5.56%	7.05%
1 Month Performance	-1.24%	13.82%	9.44%	8.85%
1 Year Performance	-99.62%	20.37%	28.74%	10.96%

GRI Bio Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTR 9 Meters Biopharma	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$1.04M	N/A	-0.02	20
GNPX Genprex	4.599 of 5 stars 4.60 / 5 stars	$0.39 -7.1%	$10.00 +2,457.5%	-98.1%	$1.01M	N/A	0.00	20	Gap Down High Trading Volume
SLRX Salarius Pharmaceuticals	1.6649 of 5 stars 1.66 / 5 stars	$1.64 +5.1%	N/A	-76.1%	$979,000.00	$1.84M	-0.08	20	Positive News
HSTO Histogen	0 of 5 stars 0.00 / 5 stars	$0.22 flat	N/A	-68.0%	$929,000.00	$19,000.00	-0.08	20
PKBO Peak Bio	0 of 5 stars 0.00 / 5 stars	$0.04 flat	N/A	-88.5%	$925,000.00	$370,000.00	0.00	3	News Coverage
LSDI Lucy Scientific Discovery	0 of 5 stars 0.00 / 5 stars	N/A	N/A	-92.1%	$907,000.00	$16,732.00	-0.07	2
ENTO Entero Therapeutics	1.701 of 5 stars 1.70 / 5 stars	$0.37 +5.8%	N/A	N/A	$906,000.00	N/A	0.00	9	Positive News Gap Up
PXMD PaxMedica	1.285 of 5 stars 1.29 / 5 stars	$0.08 flat	$3.00 +3,629.0%	-98.5%	$875,000.00	N/A	0.00	2	Gap Up
ADXS Ayala Pharmaceuticals	0 of 5 stars 0.00 / 5 stars	$0.02 flat	N/A	-97.7%	$853,000.00	$10,000.00	0.00	20	Analyst Forecast News Coverage
EVFM Evofem Biosciences	0.5951 of 5 stars 0.60 / 5 stars	$0.01 flat	N/A	-94.4%	$795,000.00	$11.39M	0.00	120	Gap Up